Table 2.
Predictors of thalidomide response among patients with β-thalassemia.
| Variable | MaR(n=41) | MiR+NR(n=21) | P value |
|---|---|---|---|
| Sex (n,%) | |||
| Male | 20 (48.8%) | 7 (33.3%) | |
| Female | 21 (51.2%) | 14 (66.7%) | 0.110 |
| Age (years) | 27.00±7.97 | 27.67±7.90 | 0.485 |
| Phenotype (n,%) | |||
| NTDT | 28 (68.3%) | 11 (52.4%) | 0.220 |
| TDT | 13 (31.7%) | 10 (47.6%) | |
| Splenic status (n,%) | |||
| Splenectomized | 15 (36.6%) | 14 (66.7%) | 0.025 |
| Nonsplenectomized | 26 (63.4%) | 7 (33.3%) | |
| Duration of treatment (month) | 15.24±9.79 | 13.42±9.29 | 0.703 |
| Thalidomide dose(mg/day) | |||
| Median (IQR) | 50 (50–50) | 50 (50–50) | 0.545 |
| Hemoglobin before Thalidomide (g/dl) | 63.76±13.49 | 68.29±13.61 | 0.217 |
| Fetal Hemoglobin before Thalidomide (%) | 46.14±22.09 | 28.49±20.54 | 0.003 |
Abbreviations: MaR: main responder; MiR: minor responder; NR: no responder; NTDT: non-transfusion-dependent thalassemia; TDT: transfusion-dependent thalassemia; IQR: interquartile range.